Roth Capital Initiates Coverage of Atrium Therapeutics, Inc. with Buy Rating

On October 22, 2026, Roth Capital initiated coverage of Atrium Therapeutics, Inc. (Ticker: RNA) with a Buy rating. This action indicates a positive outlook from the firm regarding the biopharmaceutical company's market position.